Tyra Biosciences (NASDAQ:TYRA) Earns “Buy” Rating from HC Wainwright

Tyra Biosciences (NASDAQ:TYRA)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $45.00 price target on the stock. HC Wainwright’s price target points to a potential upside of 58.34% from the stock’s current price.

Several other equities research analysts have also recently weighed in on TYRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research note on Friday, July 17th. JonesTrading began coverage on Tyra Biosciences in a research report on Wednesday, June 17th. They set a “buy” rating and a $56.00 price objective for the company. Bank of America boosted their target price on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Jefferies Financial Group reiterated a “buy” rating and issued a $42.00 price target on shares of Tyra Biosciences in a research note on Wednesday, August 5th. Finally, Wolfe Research began coverage on shares of Tyra Biosciences in a research note on Tuesday, May 19th. They issued a “peer perform” rating for the company. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tyra Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $48.22.

Tyra Biosciences Stock Up 14.3%

Shares of TYRA traded up $3.56 during mid-day trading on Friday, hitting $28.42. 867,555 shares of the company’s stock traded hands, compared to its average volume of 865,043. Tyra Biosciences has a 1 year low of $11.70 and a 1 year high of $40.65. The firm has a market capitalization of $1.70 billion, a P/E ratio of -11.82 and a beta of 0.73. The business’s 50-day moving average price is $29.09 and its 200-day moving average price is $32.05.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). Sell-side analysts anticipate that Tyra Biosciences will post -2.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Tyra Biosciences

Large investors have recently modified their holdings of the stock. Hilton Head Capital Partners LLC purchased a new stake in Tyra Biosciences during the 1st quarter valued at about $30,000. Caitong International Asset Management Co. Ltd purchased a new position in Tyra Biosciences in the fourth quarter worth about $51,000. State of Wyoming purchased a new position in Tyra Biosciences in the second quarter worth about $76,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Tyra Biosciences by 14.5% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after buying an additional 1,668 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Tyra Biosciences by 27.7% in the third quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock worth $178,000 after buying an additional 2,766 shares in the last quarter. Hedge funds and other institutional investors own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.